Melissa A. Johnson

Melissa A. Johnson

Auto-generated profile, based on publicly available information

Melissa A. Johnson

Salk Institute for Biological Studies, La Jolla, CA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2025 in Science
Verified
Journal Article
Closed access
SVSiva Karthik Varanasi
Siva Karthik Varanasi
DCDan Chen
Dan Chen
YLYingluo Liu
Yingluo Liu
MJMelissa A. Johnson
Melissa A. Johnson
CMCayla M. Miller
Cayla M. Miller
SKSusan M. Kaech
Susan M. Kaech
The metabolic landscape of cancer greatly influences antitumor immunity, yet it remains unclear how organ-specific metabolites in the tumor microenvironment influence immunosurveillance. We found that accumulation of primary conjugated and secondary bile acids (BAs) are metabolic features of human hepatocellular carcinoma and experimental liver cancer models. Inhibiting conjugated BA synthesis in hepatocytes through deletion of the BA-conjugating enzyme bile acid–CoA:amino acid N -acyltransferase (BAAT) enhanced tumor-specific T cell responses, reduced tumor growth, and sensitized tumors to anti–programmed cell death protein 1 (anti–PD-1) immunotherapy. Furthermore, different BAs regulated CD8 + T cells differently; primary BAs induced oxidative stress, whereas the secondary BA lithocholic acid inhibited T cell function through endoplasmic reticulum stress, which was countered by ursodeoxycholic acid. We demonstrate that modifying BA synthesis or dietary intake of ursodeoxycholic acid could improve tumor immunotherapy in liver cancer model systems.

22 September 2023 in Science
Verified
Journal Article
Closed access
KMKailash Chandra Mangalhara
Kailash Chandra Mangalhara
SVSiva Karthik Varanasi
Siva Karthik Varanasi
MJMelissa A. Johnson
Melissa A. Johnson
MBMannix Burns
Mannix Burns
GRGladys R. Rojas
Gladys R. Rojas
GSGerald S. Shadel
Gerald S. Shadel
Although tumor growth requires the mitochondrial electron transport chain (ETC), the relative contribution of complex I (CI) and complex II (CII), the gatekeepers for initiating electron flow, remains unclear. In this work, we report that the loss of CII, but not that of CI, reduces melanoma tumor growth by increasing antigen presentation and T cell–mediated killing. This is driven by succinate-mediated transcriptional and epigenetic activation of major histocompatibility complex–antigen processing and presentation (MHC-APP) genes independent of interferon signaling. Furthermore, knockout of methylation-controlled J protein (MCJ), to promote electron entry preferentially through CI, provides proof of concept of ETC rewiring to achieve antitumor responses without side effects associated with an overall reduction in mitochondrial respiration in noncancer cells. Our results may hold therapeutic potential for tumors that have reduced MHC-APP expression, a common mechanism of cancer immunoevasion.

27 January 2025 in Journal of Cell Biology
Verified
Journal Article
Closed access
ASAlva G. Sainz
Alva G. Sainz
GRGladys R. Rojas
Gladys R. Rojas
AMAlexandra G. Moyzis
Alexandra G. Moyzis
MDMatthew P. Donnelly
Matthew P. Donnelly
KMKailash C. Mangalhara
Kailash C. Mangalhara
GSGerald S. Shadel
Gerald S. Shadel
Mitochondrial retrograde signaling (MRS) pathways relay the functional status of mitochondria to elicit homeostatic or adaptive changes in nuclear gene expression. Budding yeast have “intergenomic signaling” pathways that sense the amount of mitochondrial DNA (mtDNA) independently of oxidative phosphorylation (OXPHOS), the primary function of genes encoded by mtDNA. However, MRS pathways that sense the amount of mtDNA in mammalian cells remain poorly understood. We found that mtDNA-depleted IMR90 cells can sustain OXPHOS for a significant amount of time, providing a robust model system to interrogate human intergenomic signaling. We identified FAM43A, a largely uncharacterized protein, as a CHK2-dependent early responder to mtDNA depletion. Depletion of FAM43A activates a mitochondrial biogenesis program, resulting in an increase in mitochondrial mass and mtDNA copy number via CHK2-mediated upregulation of the p53R2 form of ribonucleotide reductase. We propose that FAM43A performs a checkpoint-like function to limit mitochondrial biogenesis and turnover under conditions of mtDNA depletion or replication stress.

4 September 2026 in Science Advances
Verified
Journal Article
Open access
MDMatthew P. Donnelly
Matthew P. Donnelly
KMKailash Chandra Mangalhara
Kailash Chandra Mangalhara
YLYuening Liu
Yuening Liu
KLKathryn Lande
Kathryn Lande
GRGladys R. Rojas
Gladys R. Rojas
GSGerald S. Shadel
Gerald S. Shadel
Mitohormesis, whereby transient mitochondrial stress induces adaptive signaling, promotes organismal resilience and longevity in invertebrates, but how this operates in mammals and the underlying metabolic signals involved remain unclear. Using a mouse model of mitohormesis, we show that transient mitochondrial superoxide stress during embryogenesis reprograms the adult heart to enhance mitochondrial biogenesis and antioxidant capacity. These adaptations confer protection against mitochondrial and oxidative injury in models of doxorubicin-induced cardiotoxicity, preserving mitochondrial content and preventing cardiac dysfunction and remodeling. Using a cell model of superoxide-mediated mitohormesis, we find that inhibition of mitochondrial aconitase promotes citrate export to the cytosol, where its conversion to acetyl–coenzyme A drives histone acetylation and mitohormetic protection from oxidative stress. Preventing mitochondrial citrate export abolishes these adaptations, while Aco2 silencing or citrate supplementation recapitulates the response. Together, our findings identify mitochondrial citrate as a redox-sensitive second messenger linking mitochondrial superoxide stress to durable epigenetic and mitohormetic remodeling.

10 September 2026 in Science
Verified
Journal Article
Closed access
MJMelissa A. Johnson
Melissa A. Johnson
SVSiva Karthik Varanasi
Siva Karthik Varanasi
KMKailash Chandra Mangalhara
Kailash Chandra Mangalhara
KLKathryn Lande
Kathryn Lande
GRGladys R. Rojas
Gladys R. Rojas
GSGerald S. Shadel
Gerald S. Shadel
Interferons (IFNs) are proinflammatory cytokines that promote immune cell engagement to eliminate malignant cells. Paradoxically, chronic interferon signaling can also activate anti-inflammatory mechanisms that allow cancer cells to evade the immune system. In this study, we sought to determine the cellular mechanisms underlying this switch from antitumorigenic to protumorigenic interferon activity. We show that chronic type II interferon (IFN-II) exposure distinctively induced tumor growth by activating a type I interferon (IFN-I) response mediated by release of double-stranded mitochondrial RNA (ds-mtRNA) into the cytoplasm. This IFN-I signal synergized with IFN-II to enhance tumor growth by increasing immunosuppressive prostaglandin E 2 (PGE 2 ) synthesis through increased cyclooxygenase 2 expression. Elimination of PGE 2 synthesis in immunotherapy-resistant melanoma cells restored their responsiveness to anti-PD1 treatment, indicating that this covert mtRNA-IFN-prostaglandin pathway could be a therapeutic target to combat immunotherapy resistance.